Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Johnson & Johnson    JNJ   US4781601046

JOHNSON & JOHNSON (JNJ)

213
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

05/07/2012 | 05:51pm US/Eastern
Recommend:
0
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Recommend :
0
React to this article
Latest news on JOHNSON & JOHNSON
6h ago JOHNSON & JOHNSON : New Data Show Once-Daily XARELTO® May Be an Alternative to V..
1d ago Pricing is key for new heart drugs challenging cheap generics
1d ago ZIMMER : EU decision on Zimmer's $13.4 billion Biomet deal expected by October 3
3d ago JOHNSON & JOHNSON : National Talcum Powder Attorneys Expand Website to Different..
4d ago JOHNSON & JOHNSON : Statement by Secretary Johnson on President Obama's Intent t..
4d ago JOHNSON & JOHNSON : Janssen Expands EXPLORER Global Cardiovascular Research Prog..
4d ago JOHNSON & JOHNSON : Janssen Diagnostics Expands Research Portfolio to Include Ne..
5d ago JOHNSON & JOHNSON : Ethicon Expands Bariatric Surgery Portfolio; Unveils “..
5d ago JOHNSON & JOHNSON : Janssen Affiliate Cilag GmbH International Acquires Covagen ..
5d ago JOHNSON & JOHNSON : Reform in Health Financing Key to Universal and Affordable H..
Advertisement
Chart
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Income Statement Evolution
Johnson _ Johnson : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF